ALT
Price
$3.50
Change
-$4.21 (-54.60%)
Updated
Jun 27 closing price
Capitalization
283.87M
40 days until earnings call
IMAB
Price
$2.57
Change
+$0.55 (+27.23%)
Updated
Jun 27 closing price
Capitalization
209.05M
66 days until earnings call
Interact to see
Advertisement

ALT vs IMAB

Header iconALT vs IMAB Comparison
Open Charts ALT vs IMABBanner chart's image
Altimmune
Price$3.50
Change-$4.21 (-54.60%)
Volume$20.04M
Capitalization283.87M
I-MAB
Price$2.57
Change+$0.55 (+27.23%)
Volume$2.59M
Capitalization209.05M
ALT vs IMAB Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. IMAB commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and IMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (ALT: $3.50 vs. IMAB: $2.56)
Brand notoriety: ALT and IMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 506% vs. IMAB: 423%
Market capitalization -- ALT: $283.87M vs. IMAB: $209.05M
ALT [@Biotechnology] is valued at $283.87M. IMAB’s [@Biotechnology] market capitalization is $209.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileIMAB’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • IMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, IMAB is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 4 TA indicator(s) are bullish while IMAB’s TA Score has 5 bullish TA indicator(s).

  • ALT’s TA Score: 4 bullish, 5 bearish.
  • IMAB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IMAB is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а -48.38% price change this week, while IMAB (@Biotechnology) price change was +2.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

IMAB is expected to report earnings on Sep 02, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($284M) has a higher market cap than IMAB($209M). IMAB YTD gains are higher at: 201.176 vs. ALT (-51.456). IMAB has higher annual earnings (EBITDA): -46.92M vs. ALT (-90.75M). IMAB has more cash in the bank: 169M vs. ALT (150M). ALT has less debt than IMAB: ALT (1.59M) vs IMAB (3.68M). ALT has higher revenues than IMAB: ALT (20K) vs IMAB (0).
ALTIMABALT / IMAB
Capitalization284M209M136%
EBITDA-90.75M-46.92M193%
Gain YTD-51.456201.176-26%
P/E RatioN/AN/A-
Revenue20K0-
Total Cash150M169M89%
Total Debt1.59M3.68M43%
FUNDAMENTALS RATINGS
ALT: Fundamental Ratings
ALT
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALTIMAB
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 20 days ago
77%
Declines
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JBAFX30.16N/A
N/A
JHancock Balanced R4
IIRSX12.02N/A
N/A
Voya Russell Small Cap Index Port I
GLCUX34.75N/A
N/A
Goldman Sachs Large Cap Gr Insghts R6
KGDZX31.95N/A
N/A
DWS Global Small Cap R6
OWLLX10.54N/A
N/A
Channing Intrinsic Value Sm-Cp Instl

IMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
+26.73%
VCYT - IMAB
43%
Loosely correlated
+2.13%
ALT - IMAB
34%
Loosely correlated
-54.60%
ARRY - IMAB
31%
Poorly correlated
-0.77%
IKNA - IMAB
30%
Poorly correlated
+0.75%
AXON - IMAB
29%
Poorly correlated
+1.82%
More